ALK – Epidemiology – Mature Markets Data

Clarivate Epidemiology’s coverage of anaplastic lymphoma kinase (ALK) comprises epidemiological estimates of key patient populations with the biomarker in the major mature pharmaceutical markets (the United States, France, Germany, Italy, Spain, the United Kingdom, and Japan). We report the incidence of ALK for each country, as well as annualized case counts projected to the national population.

The patient populations are forecast over a period of 10 years for the countries covered in this report. In addition to forecasting incident patient populations, we estimate the number of drug-treatment opportunities in specific lines of therapy.

Clarivate Epidemiology’s ALK forecast will answer the following questions:

• How will improvements in survival change the number of people living with a diagnosis of ALK-mutated cancer?
• Of all people diagnosed with ALK-mutated cancer, how many in each of the major mature pharmaceutical markets are drug-treated?
• How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of ALK over the forecast period?

All forecast data are available on the Clarivate Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.

In total, Clarivate Epidemiology forecasts 44 ALK-mutated cancer populations, including the following:

• Diagnosed incident cases of ALK-mutated cancer by primary tumor site.
• Diagnosed incident cases of ALK-mutated cancer by metastatic status.
• Diagnosed first-line drug-treatable population of ALK-mutated cancer by site of primary tumor.
• … and many more (details available on request).

Note: Coverage may vary by country.